H S Goei The
Overview
Explore the profile of H S Goei The including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gerards A, Landewe R, Prins A, Bruyn G, Goei The H, Laan R, et al.
Ann Rheum Dis
. 2003 Mar;
62(4):291-6.
PMID: 12634224
Objective: To compare the efficacy and toxicity of cyclosporin A (CsA) monotherapy with CsA plus methotrexate (MTX) combination therapy in patients with early rheumatoid arthritis (RA). Patients And Methods: 120...
2.
van den Borne B, Landewe R, Rietveld J, Goei The H, Griep E, Breedveld F, et al.
Clin Rheumatol
. 1999 Oct;
18(5):369-72.
PMID: 10524550
If rheumatoid arthritis (RA) patients with a mild disease course could be identified early in the phase of the disease, therapy with less aggressive and probably less toxic antirheumatic drugs...
3.
van den Borne B, Landewe R, Goei The H, Breedveld F, Dijkmans B
Rheumatology (Oxford)
. 1999 May;
38(3):254-9.
PMID: 10325664
Objectives: To investigate (1) whether the increase in serum creatinine observed during cyclosporin A (CsA) therapy was reversible in a group of patients with rheumatoid arthritis (RA) treated before the...
4.
van den Borne B, Landewe R, Houkes I, Schild F, van der Heyden P, Hazes J, et al.
Arthritis Rheum
. 1998 Nov;
41(11):1930-7.
PMID: 9811046
Objective: To evaluate the cyclosporin A (CSA)-attributed risk of developing malignancies in general and malignant lymphoproliferative diseases (LPDs) and skin cancers in particular, as well as the CSA-attributed incidence of...
5.
van den Borne B, Landewe R, Goei The H, Rietveld J, Zwinderman A, Bruyn G, et al.
J Rheumatol
. 1998 Aug;
25(8):1493-8.
PMID: 9712089
Objective: To investigate whether there is interaction between chloroquine and cyclosporine (CyA) at the level of efficacy and toxicity in patients with recent onset rheumatoid arthritis (RA). Methods: Eighty-eight patients...
6.
Goei The H, Lund B, Distel M, Bluhmki E
Osteoarthritis Cartilage
. 1997 Jul;
5(4):283-8.
PMID: 9404473
Meloxicam is a new nonsteroidal anti-inflammatory drug (NSAID), which, in animal tests, displays a high potency for anti-inflammatory and analgesic action. The aim of this study was to investigate the...
7.
van den Borne B, Landewe R, Goei The H, Mattie H, Breedveld F, Dijkmans B
Br J Clin Pharmacol
. 1995 Feb;
39(2):172-5.
PMID: 7742156
The relative bioavailability of cyclosporin A (CsA) from a new microemulsion oral formulation (NEO) and the currently used soft gelatine capsule (SGC) was determined at steady state in 12 patients...
8.
Landewe R, Goei The H, van Rijthoven A, Rietveld J, Breedveld F, Dijkmans B
J Rheumatol
. 1994 Sep;
21(9):1631-6.
PMID: 7799340
Objective: To investigate in common clinical practice the toxicity/efficacy ratio of low dose cyclosporine A (CsA) in patients with advanced rheumatoid arthritis (RA) after 12 months CsA administration. Methods: One...
9.
Landewe R, Goei The H, van Rijthoven A, Breedveld F, Dijkmans B
Arthritis Rheum
. 1994 May;
37(5):637-43.
PMID: 8185690
Objective: To investigate whether low-dose cyclosporin A (CSA) is safe and effective in comparison with chloroquine (CQ) in patients with early rheumatoid arthritis (RA). Methods: We performed a randomized, double-blind...
10.
Dijkmans B, van Rijthoven A, Goei The H, Boers M, Cats A
Semin Arthritis Rheum
. 1992 Aug;
22(1):30-6.
PMID: 1411580
The efficacy and toxicity of cyclosporine in the treatment of patients with rheumatoid arthritis (RA) are reviewed. Most of the early trials were restricted to patients with intractable RA. The...